领航医药生物科技(0399.HK)今日早盘一度大跌22.12%至0.405港元，股价创7月21日以来近2个月新低。 领航医药生物科技昨日晚间公告，内容有关公司与中国北方证券集团有限公司(作为配售代理)所订立日期为2025年8月21日的配售协议，以按配售价每股配 售股份0.415港元认购最多1.45亿股公司配售股份。董事会宣布，由于配售协议所载的先决条件未能于2025年9月11日或之前达成，配售协议已失效且配售事 项将不会进行。 据悉，领航医药生物科技今年8月21日曾公告，拟发行1.45亿股配售股份净筹5882.5万港元。公司拟将配售事项所得款项净额全数用作集团的于发展区块链技 术业务资金。公告发布翌日(8月22日)，该股大幅收涨10.87%。(格隆汇) ...

Core Viewpoint - The stock of Pioneer Pharma Biotechnology (00399) has dropped over 19% following the expiration of a share placement agreement aimed at raising HKD 60.18 million, which failed to meet its conditions by the deadline of September 11 [1] Group 1: Stock Performance - As of the report, Pioneer Pharma's stock is down 19.23%, trading at HKD 0.42, with a trading volume of HKD 16.28 million [1] Group 2: Share Placement Agreement - The company announced that the share placement agreement for a maximum of 145 million new shares has become invalid due to unmet conditions [1] - The board believes that the failure of the placement agreement will not have any significant adverse impact on the company's current operations and financial status [1] Group 3: Previous Announcements - On August 21, the company had previously announced a plan to place shares at HKD 0.415 each, aiming to raise approximately HKD 58.83 million, which was intended for funding the development of blockchain technology [1]

Core Viewpoint - The company, Pioneer Pharmaceuticals Biotechnology (00399), has announced a placement agreement to issue up to 145 million shares at a price of HKD 0.415 per share, which represents a discount of approximately 9.78% from the closing price of HKD 0.46 on August 21, 2025 [1] Group 1 - The placement is expected to involve at least six independent third-party subscribers [1] - If all shares are fully placed, the total proceeds from the placement will be approximately HKD 60.175 million [1] - After deducting related expenses of about HKD 1.35 million, the estimated net proceeds will be around HKD 58.825 million [1] Group 2 - The net proceeds from the placement are intended to be used entirely for funding the company's blockchain technology business development [1]